Search results for "E-F"

showing 10 items of 836 documents

Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

2013

ObjectivesThis study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC).MethodsA retrospective case-control study including all patients with SEOC who had been treated at 5 European tertiary gynecologic oncology centers between 1996 and 2011 and patients with either EC or OC matched for age, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, year of diagnosis, and Eastern Cooperative Oncology Group performance score.ResultsThe study cohort comprised 77, 132, and 126 patients with SEOC, EC, and OC, respectively. The patient characteristics …

medicine.medical_specialtyMedizinGynecologic oncologyDisease-Free SurvivalCohort StudiesNeoplasms Multiple PrimaryTertiary Care CentersGermanymedicineHumansStage (cooking)Retrospective StudiesOvarian NeoplasmsGynecologybusiness.industryEndometrial cancerCarcinomaCase-control studyObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseaseEndometrial NeoplasmsOncologyCase-Control StudiesCohortFemalebusinessOvarian cancerCohort studyInternational Journal of Gynecologic Cancer
researchProduct

Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study.

2020

<b><i>Introduction:</i></b> Evidence that smoking cessation at first diagnosis of nonmuscle-invasive bladder cancer (NMIBC) reduces the risk of recurrence is lacking. The aim of our prospective study was to analyze the association between patients’ changes in smoking habits after diagnosis and recurrence-free survival (RFS). <b><i>Patients:</i></b> After transurethral resection of primary NMIBC, patients were classified as “ex-smokers,” i.e., those definitively stopping, and as “active smokers,” i.e., those continuing or restarting to smoke. Smoking status was reassessed every 3 months during the first year and every 6 months thereafter. Data …

medicine.medical_specialtyMultivariate analysisUrologymedicine.medical_treatmentDisease-Free SurvivalRecurrence riskCigarette smokingRecurrenceInternal medicinemedicineNonmuscle-invasive bladder cancerHumansStatistical analysisNeoplasm InvasivenessProspective StudiesProspective cohort studyPathologicalAgedBladder cancerbusiness.industryMiddle Agedmedicine.diseasePrimary tumorUrinary Bladder NeoplasmsSmoking cessationSmoking CessationNeoplasm Recurrence LocalbusinessUrologia internationalis
researchProduct

Annual Trends in Total Ischemic Time and One-Year Fatalities: The Paradox of STEMI Network Performance Assessment

2019

This study is aimed at assessing trends and relations between total ischemic time, the major quality measure of systemic delay, and case-fatality at the population or patient level in response to growing cardiovascular risk and a constant need to shorten the time to treatment in ST-segment elevation myocardial infarction (STEMI). Data from a prospective nationwide registry of STEMI patients admitted between 2006 and 2013 who were treated with primary percutaneous coronary intervention (PCI) were analyzed. Total ischemic time was calculated as the time from the onset of symptoms to primary PCI and was determined as individual and annual. The primary end-point was one-year, all-cause case-fat…

medicine.medical_specialtyMultivariate analysismedicine.medical_treatmentPopulationlcsh:MedicineIschemic time030204 cardiovascular system & hematologyArticleSTEMI03 medical and health sciencestotal ischemic time0302 clinical medicineInternal medicineCase fatality ratemedicinecase-fatality030212 general & internal medicineMyocardial infarctioncardiovascular diseasesRisk factoreducationeducation.field_of_studybusiness.industrylcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseConventional PCInetworkCardiologybusinessJournal of Clinical Medicine
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

Long-Segment Early Squamous Cell Carcinoma of the Proximal Esophagus: Curative Treatment and Long-Term Follow-Up after 5-Aminolevulinic Acid (5-ALA)-…

2006

Photodynamic therapy (PDT) is an established treatment for the ablation of dysplastic Barrett's epithelium and early esophageal carcinoma, but no data have been published on curative 5-aminolevulinic acid (5-ALA)-PDT for long-segment early esophageal cancer with infiltration of the upper sphincter. We describe successful curative treatment of an unusual early long-segment squamous cell carcinoma (uT1a,N0) of the proximal esophagus (18 - 28 cm aborally), with three sessions of 5-ALA-PDT. Endoscopic and endosonographic follow-up macroscopically showed a complete remission of the tumor, proven by biopsy showing total histological ablation. After a follow-up period of 23 months, there has been …

medicine.medical_specialtyTime FactorsEsophageal NeoplasmsBiopsymedicine.medical_treatmentPhotodynamic therapyGastroenterologyDisease-Free SurvivalEndoscopy GastrointestinalInternal medicineBiopsymedicineCarcinomaHumansEsophagusPhotosensitizing Agentsmedicine.diagnostic_testbusiness.industryGastroenterologyAminolevulinic AcidMiddle AgedEsophageal cancerAblationmedicine.diseaseEndoscopymedicine.anatomical_structurePhotochemotherapyEpidermoid carcinomaCarcinoma Squamous CellbusinessFollow-Up StudiesEndoscopy
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

Angiographic co-registration of instantaneous wave-free ratio and intravascular ultrasound improves functional assessment of borderline lesions in th…

2018

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryCo registration030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureText miningImage in InterventionIntravascular ultrasoundmedicineRadiologyInstantaneous wave-free ratioCardiology and Cardiovascular MedicinebusinessArteryPostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer

2007

Abstract Background. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) contribute to the invasiveness of many carcinomas. Here, we studied a possible association between cytosolic uPA and PA-1 concentrations in tumor tissue with prognosis in patients with endometrial cancer. Methods. Cytosolic concentrations of uPA and PAI-1 were determined in 69 primary endothelial adenocarcinomas using an enzyme-linked immunoassay (ELISA). A possible influence of uPA and PAI-1 was studied by multivariate Cox regression adjusting for the established clinical prognostic factors FIGO-stage, grading, depth of invasion, diabetes mellitus and age. Results. Both uPA ( …

medicine.medical_specialtymedicine.drug_classAdenocarcinomaDisease-Free SurvivalMetastasisPredictive Value of TestsGermanyInternal medicineDiabetes mellitusPlasminogen Activator Inhibitor 1Progesterone receptorBiomarkers TumormedicineHumansNeoplasm StagingUrokinasebusiness.industryProportional hazards modelEndometrial cancerObstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorEndometrial NeoplasmsEndocrinologyOncologyEstrogenFemalebusinessPlasminogen activatormedicine.drugGynecologic Oncology
researchProduct

Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Ana…

2020

Abstract Purpose Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS). Patients and Methods Data for stage IB2–IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical respons…

medicine.medical_specialtymedicine.medical_treatmentConcomitant Chemoradiation Neoadjuvant Chemotherapy Phase III Hysterectomy Radiation Therapy WomenUterine Cervical NeoplasmsHysterectomyDisease-Free Survival03 medical and health sciences0302 clinical medicinePhase IIIlocally advanced cervical cancer (LACC)locally advanced cervical cancerHumansMedicineWomenChemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Uterine Cervical Neoplasms030212 general & internal medicineStage (cooking)Radical surgeryPropensity ScoreNeoadjuvant therapyNeoplasm StagingRetrospective StudiesCervical cancerHysterectomyRadiationbusiness.industrylocally advanced cervical cancer surgeryNeoadjuvant ChemotherapyRetrospective cohort studyChemoradiotherapyGynecologic Oncologymedicine.diseaseNeoadjuvant TherapySurgeryRadiation therapySettore MED/40 - GINECOLOGIA E OSTETRICIANeoplasm RecurrenceLocalOncology030220 oncology & carcinogenesisConcomitant ChemoradiationFemaleSurgeryTherapyNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Advances in surfaces and osseointegration in implantology. Biomimetic surfaces

2015

The present work is a revision of the processes occurring in osseointegration of titanium dental implants according to different types of surfaces -namely, polished surfaces, rough surfaces obtained from subtraction methods, as well as the new hydroxyapatite biomimetic surfaces obtained from thermochemical processes. Hydroxyapatite’s high plasma-projection temperatures have proven to prevent the formation of crystalline apatite on the titanium dental implant, but lead to the formation of amorphous calcium phosphate (i.e., with no crystal structure) instead. This layer produce some osseointegration yet the calcium phosphate layer will eventually dissolve and leave a gap between the bone and …

medicine.medical_treatmentDentistryintegrationReviewcoatingsApatitelaw.inventionlawBiomimetic MaterialsImplants surfacesbioactive titaniumBiomimetics surfacesAmorphous calcium phosphateComposite materialCrystallizationDental implantTitaniumSuperfícies biomimètiquesImplantes dentalesSuperfícies d’implants:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludbone-formation adjacentSuperficies biomiméticasvisual_artUNESCO::CIENCIAS MÉDICASvisual_art.visual_art_mediumacidvivoLayer (electronics)biomimetics surfacesTitaniumMaterials scienceSurface Propertiesproliferationchemistry.chemical_elementOdontología616.3in-vitro:Enginyeria dels materials [Àrees temàtiques de la UPC]OsseointegrationBacterial colonizationfibronectinOsseointegrationmedicineAnimalsHumansGeneral DentistryBlood CoagulationDental ImplantsOral Medicine and PathologyImplants dentalsbusiness.industryDental implantsosseointegrationTitaniimplants surfacesSuperficies de implantesOtorhinolaryngologychemistryOsteointegraciónSurgerybusinessOsteointegració
researchProduct